A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
World leaders past and present have gathered in Israel for the funeral of the country's former prime minister and president Shimon Peres.
The newspaper's latest claims surround Eric Black, who allegedly offered advice on how to bribe officials at other clubs.
One of the most ambitious space missions ever embarked on will end at around 12.20pm today.